Blood Group Typing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Consumables, Instruments, Services), By Technique (PCR-Based and Microarray Techniques, Assay-Based Techniques, Massively Parallel Sequencing, Others), By Test Type (Antibody Screening, HLA Typing, ABO Blood Tests, Cross-Matching Tests, Antigen Typing), By End User (Hospitals, Clinical Laboratories, Blood Banks, Other End Users), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.42 Billion
CAGR (2026-2031)	8.94%
Fastest Growing Segment	Assay-Based Techniques
Largest Market	North America
Market Size (2031)	USD 4.05 Billion

Market Overview

The Global Blood Group Typing Market will grow from USD 2.42 Billion in 2025 to USD 4.05 Billion by 2031 at a 8.94% CAGR. Blood group typing is the diagnostic process of identifying specific ABO and Rh antigens on the surface of red blood cells to ensure serological compatibility prior to transfusion. The market is primarily driven by the increasing global prevalence of chronic hematologic disorders and a rising incidence of trauma cases requiring immediate blood replacement. Furthermore, the expanding volume of complex surgical procedures mandates rigorous pre-transfusion screening to guarantee patient safety, thereby sustaining a high demand for accurate typing reagents and automated assay systems across healthcare facilities.

However, the market faces a significant impediment regarding the volatility of blood supplies which disrupts consistent testing workflows. A shrinking donor base places immense pressure on inventory management, often leading to supply shortages that complicate the efficient utilization of typing resources. For instance, according to the American Red Cross, in 2024, the national blood inventory plummeted by more than 25 percent in July due to persistent donor shortages. Such instability in the supply chain creates operational challenges that can hinder the steady expansion of the blood group typing market.

Key Market Drivers

Technological advancements in automated and molecular blood typing solutions are fundamentally reshaping the market by enhancing diagnostic accuracy and operational throughput. Laboratories are increasingly shifting from manual methods to fully automated platforms that minimize human error and standardize ABO/Rh typing results. This transition is financially evident in the performance of major industry players who supply these critical diagnostic systems. According to Grifols, February 2025, in the 'Full Year 2024 Results', their Blood Typing Solutions division delivered double-digit growth in key international markets, a surge attributed largely to the accelerated adoption of these automated instruments. Such technologies not only improve speed but also ensure high-volume processing capabilities, which are essential for maintaining steady workflows in large-scale blood centers.

Simultaneously, the increasing incidence of trauma cases requiring transfusion is a primary engine for market expansion. Emergency medicine relies heavily on immediate and precise blood grouping to prevent fatal transfusion reactions during critical care interventions. The demand for typing reagents is directly correlated with the volume of patients entering trauma centers who require massive blood support. According to the American Red Cross, May 2025, in the 'Trauma Season Blood Donation' press release, roughly 25 percent of all trauma patients require blood transfusions, driving an urgent need for compatible blood products. This consistent clinical demand underpins the stability of the consumables sector; for instance, according to QuidelOrtho, February 2025, in the 'Q4 and Full Year 2024 Financial Results', the company's Transfusion Medicine business achieved over 90 percent recurring revenue in 2024, highlighting the essential nature of blood typing in modern healthcare.

Download Free Sample Report

Key Market Challenges

The persistent volatility of blood supplies acts as a substantial restraint on the blood group typing market by directly limiting the volume of diagnostic procedures performed. When donor participation declines, blood centers and hospitals face immediate inventory deficits, which necessitates a reduction in the number of pre-transfusion tests conducted. This direct correlation means that a shrinking donor base results in lower utilization rates for typing reagents and automated assay platforms. Laboratories are consequently unable to maintain consistent testing throughput, leading to idle equipment capacity and a reduced frequency of procurement for essential diagnostic consumables.

These supply chain disruptions introduce operational instability that hinders long-term market planning and expansion. The unpredictability of donor turnout forces healthcare facilities to manage inventories conservatively, restricting the steady consumption of typing products. According to NHS Blood and Transplant, in July 2024, national stocks of O Negative blood dropped to just 1.6 days, requiring clinical staff to restrict usage to emergency cases. Such critical shortages stall market growth by lowering the overall demand for typing services and preventing the continuous revenue generation necessary for industry development.

Key Market Trends

The focus on customized assays for rare blood group identification is increasingly prioritizing the needs of chronically transfused patients who require precise phenotypic matching. Standard serological tests are often insufficient for preventing alloimmunization in complex cases, such as those involving sickle cell disease, necessitating the adoption of extensive donor screening programs. This clinical shift allows blood centers to manage diverse inventories more effectively and ensure compatibility for difficult-to-match recipients. According to the American Red Cross, September 2025, in the 'Sickle Cell Awareness Month' press release, the organization supported this precision demand by providing more than 300,000 sickle cell trait screenings, a critical measure for identifying compatible donors with rare antigen profiles.

Concurrently, the expansion of Human Leukocyte Antigen (HLA) typing applications is diversifying the operational scope of the blood group typing market. Laboratories are extending their diagnostic capabilities beyond traditional red cell antigens to include histocompatibility testing for organ and stem cell transplantation, utilizing advanced genomic platforms for high-resolution matching. This integration of transplant diagnostics into blood bank workflows represents a strategic broadening of services to support complex clinical interventions. According to Werfen, March 2025, in the 'Non-Financial Information Statement for 2024', the company’s dedicated Transplant division secured a 12 percent share of the market, reflecting the growing industrial emphasis on these specialized typing solutions.

Segmental Insights

Assay-based techniques represent the fastest-growing segment in the global blood group typing market due to the escalating need for precise antigen analysis and high-throughput screening. Laboratories increasingly adopt these molecular methods over traditional serology to ensure superior accuracy in donor-recipient matching and to identify rare blood phenotypes effectively. This shift is essential for minimizing adverse transfusion reactions in complex clinical cases. Additionally, the continued authorization of automated testing platforms by regulatory authorities, such as the US Food and Drug Administration, validates their safety and efficacy, further accelerating their integration into modern healthcare infrastructure.

Regional Insights

North America maintains a leading position in the Global Blood Group Typing Market, primarily driven by an advanced healthcare infrastructure and a high frequency of surgical procedures requiring blood transfusions. The region benefits significantly from the strong presence of major diagnostic companies and the early adoption of automated testing technologies. Furthermore, rigorous safety standards enforced by the U.S. Food and Drug Administration (FDA) foster market stability and encourage the approval of reliable diagnostic products. This supportive regulatory environment, combined with consistent investments in medical research, ensures the region's sustained dominance in the global landscape.

Recent Developments

• In October 2025, QuidelOrtho Corporation highlighted the recent U.S. Food and Drug Administration (FDA) approval of its Micro Typing Systems (MTS) DAT Card during the Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. This new gel-based product completes the company’s portfolio for direct antiglobulin testing and is designed to be used with the ORTHO VISION platform. The approval represents a significant advancement in automating transfusion medicine workflows, offering laboratories improved efficiency and standardization for detecting antibodies that coat red blood cells. The company showcased this innovation to demonstrate its continued leadership in providing integrated solutions for the global transfusion medicine community.
• In October 2024, Werfen completed the acquisition of Omixon, a Budapest-based biotechnology company specializing in Next Generation Sequencing (NGS) technologies for transplant diagnostics. This strategic expansion enhances Werfen's portfolio in the specialized diagnostics market, specifically bolstering its capabilities in Histocompatibility and Immunogenetics (HLA) testing. The acquisition aligns with the company's long-term goal of providing comprehensive solutions for hospitals and clinical laboratories to improve patient care in transplantation. By integrating Omixon's innovative NGS products and bioinformatics software, Werfen strengthens its position as a global leader in the transfusion and transplant diagnostic sectors, offering advanced tools for donor-recipient matching.
• In September 2024, AliveDx announced that it had received IVDR-CE mark certification for its MosaiQ AiPlex Celiac Disease microarray, expanding the capabilities of its multiplexing diagnostic platform. This regulatory milestone allows the company to commercialize the new microarray in the European Union and other markets that accept the CE mark. The assay is designed to streamline the diagnosis of celiac disease by enabling the simultaneous detection of relevant antibodies and IgA deficiency in a single test. This development underscores the company's commitment to leveraging its proprietary MosaiQ technology to transform transfusion diagnostics and clinical disease screening through automation and consolidated testing.
• In April 2024, Grifols announced the launch of its fully automated Erytra Eflexis analyzer in the Chinese market following the receipt of regulatory approval. This system, which utilizes the company's proprietary DG Gel technology, is designed to enhance efficiency and flexibility in immunohematology laboratories by performing complex pretransfusion compatibility testing. The launch marks a significant milestone for the company in China, where it has operated for over two decades, and aims to support the country's growing need for safe blood transfusion solutions. The analyzer's adaptable configuration allows for optimized workflow management in mid-sized to large laboratories, ensuring reliable and timely results for patient care.

Key Market Players

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Illumina, Inc.
• Immucor, Inc.
• CareDx Inc.
• Mesa Laboratories, Inc.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• AliveDx Suisse SA
• QuidelOrtho Corporation

By Product	By Technique	By Test Type	By End User	By Region
Consumables Instruments Services	PCR-Based and Microarray Techniques Assay-Based Techniques Massively Parallel Sequencing Others	Antibody Screening HLA Typing ABO Blood Tests Cross-Matching Tests Antigen Typing	Hospitals Clinical Laboratories Blood Banks Other End Users	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Blood Group Typing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood Group Typing Market, By Product:

• Consumables
• Instruments
• Services

• Blood Group Typing Market, By Technique:

• PCR-Based and Microarray Techniques
• Assay-Based Techniques
• Massively Parallel Sequencing
• Others

• Blood Group Typing Market, By Test Type:

• Antibody Screening
• HLA Typing
• ABO Blood Tests
• Cross-Matching Tests
• Antigen Typing

• Blood Group Typing Market, By End User:

• Hospitals
• Clinical Laboratories
• Blood Banks
• Other End Users

• Blood Group Typing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE